Journal Watch · European Journal of Immunology · 2026

A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell-Based Therapy.

Together, these findings provide a multimodal framework to prioritize tumor indications and improve the rational design of future NK cell clinical trials.

Chiossone L, Picant V, Barbier Q et al.European Journal of Immunology3 min readPharma relevance 65/100

DOI: 10.1002/eji.70283PMID: 42745669Study type: meta-analysis / systematic review

TL;DR

Together, these findings provide a multimodal framework to prioritize tumor indications and improve the rational design of future NK cell clinical trials.

Key findings

  • Systematic review of 177 clinical trials identified variable efficacy across solid tumor indications, without a clearly superior tumor type or intervention.
  • Transcriptomic profiling of over 10,000 TCGA samples assessed NK cell infiltration, cytotoxic fitness, and tumor microenvironment composition, highlighting kidney renal cell carcinoma, lung adenocarcinoma and squamous cell carcinoma, cervical and endocervical cancers, and mesothelioma as promising candidates for future clinical evaluation.
  • Together, these findings provide a multimodal framework to prioritize tumor indications and improve the rational design of future NK cell clinical trials.

What they did

This study integrates multiomic analyses, clinical trial data, and transcriptomic analyses to systematically identify solid tumor indications most likely to benefit from NK cell-based therapies. Immunohistochemical analysis revealed that NK cells infiltrate multiple tumor types, with the highest abundance in kidney tumors.

Full abstract (original)

Background: T cell-based immunotherapies have achieved remarkable success in hematological malignancies but remain limited in solid tumors. Natural killer (NK) cells offer a compelling complementary approach, given their ability to recognize and kill tumor cells independently of neoantigen presentation and MHC class I expression.

What they did: This study integrates multiomic analyses, clinical trial data, and transcriptomic analyses to systematically identify solid tumor indications most likely to benefit from NK cell-based therapies. Immunohistochemical analysis revealed that NK cells infiltrate multiple tumor types, with the highest abundance in kidney tumors.

Results & conclusions: Systematic review of 177 clinical trials identified variable efficacy across solid tumor indications, without a clearly superior tumor type or intervention. Transcriptomic profiling of over 10,000 TCGA samples assessed NK cell infiltration, cytotoxic fitness, and tumor microenvironment composition, highlighting kidney renal cell carcinoma, lung adenocarcinoma and squamous cell carcinoma, cervical and endocervical cancers, and mesothelioma as promising candidates for future clinical evaluation. Together, these findings provide a multimodal framework to prioritize tumor indications and improve the rational design of future NK cell clinical trials.

Abstract © the authors / European Journal of Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/eji.70283 · PubMed 42745669.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking European Journal of Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this European Journal of Immunology study find?

Together, these findings provide a multimodal framework to prioritize tumor indications and improve the rational design of future NK cell clinical trials.

What type of study is this?

It is a meta-analysis / systematic review, published in European Journal of Immunology in 2026. This study integrates multiomic analyses, clinical trial data, and transcriptomic analyses to systematically identify solid tumor indications most likely to benefit from NK cell-based therapies.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/eji.70283. PubMed ID: 42745669. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Chiossone L, Picant V, Barbier Q et al.. A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell-Based Therapy.. European Journal of Immunology (2026). DOI: 10.1002/eji.70283.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-multimodal-framework-to-guide-solid-tumor-indications-for-natural-kill-i70283/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides